December 5, 2025

ASH Annual Meeting 2025: How the MMRF is Driving New Discoveries and Collaborations

Once again, the Multiple Myeloma Research Foundation’s programs and data are the catalysts for some of the most important updates at the 2025 American Society of Hematology (ASH) Annual Meeting. The MMRF will also bring together institutional and pharma partners for a day of pre-conference meetings to share learnings, review emerging data, and more. Every […]

December 1, 2025

Lynozyfic (linvoseltamab-gcpt): Another Breakthrough for Patients With Relapsed or Refractory Myeloma

People living with multiple myeloma often relapse after several lines of therapy. When this happens, it can feel like options are running out. The recent approval of Lynozyfic (linvoseltamab-gcpt) is an important step forward in expanding treatment option for patients. Lynozyfic was approved in July 2025 for adult patients with relapsed or refractory multiple myeloma […]

November 21, 2025

Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance | Blood Cancer Journal – Nature

November 12, 2025

Mount Sinai Study Reveals Why Some Myeloma Patients Stay Cancer-Free for Years After CAR T Therapy – Mount Sinai

November 11, 2025

Multiple myeloma treatment: A roadmap for long-term care – Penn Medicine